131i-metaiodobenzylguanidine

Small moleculeexperimentalImaging agent

Clinical trial activity

8 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Nov 1, 2001 (NCT00037869)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Imaging
131-iodine

Oral

No

Parenteral

No

Topical

No

Also known as

  • 131i-metaiodobenzylguanidine
  • i-131 metaiodobenzylguanidine
  • i-131 metaiodobenzylguanidine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03015844N/AJan 5, 2017Cohen Children's Medical Center of New York, Northwell Health
NCT01850888N/ADec 1, 2013University of Minnesota
NCT02173834N/AMar 31, 2013University of Amsterdam
NCT01019850Phase 1Mar 1, 2010National Cancer Institute (NCI), University of California, San Francisco
NCT01377532N/AAug 1, 2009University of California, San Francisco
NCT01099228N/ASep 30, 2006Department of Veteran Affairs, University of Iowa
NCT01163383N/AMar 1, 2005University of Pennsylvania
NCT00037869Phase 3Nov 1, 2001University of Texas at Houston
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of California, San FranciscoAcademic/Hospital2122009
Cohen Children's Medical Center of New YorkAcademic/Hospital1012017
Department of Veteran AffairsGovernment1012006
National Cancer Institute (NCI)Government1112010
Northwell HealthAcademic/Hospital1112017
University of AmsterdamAcademic/Hospital1112013
University of IowaAcademic/Hospital1112006
University of MinnesotaAcademic/Hospital1112013
University of PennsylvaniaAcademic/Hospital1112005
University of Texas at HoustonAcademic/Hospital1112001
10 organizations
Page 1 / 1